UNION CITY, Calif., Oct. 15, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced that it has resubmitted its filing to the U.S. Food & Drug Administration (FDA) for its supplemental New Drug Application (sNDA) seeking approval to market H.P. Acthar(R) Gel (repository corticotrophin injection) for the treatment of infantile spasms. The resubmission follows the FDA's request in May 2009 for the filing to include additional statistical analysis relating to data from one secondary study within the Company's filing.
"During the past several months we've performed the additional statistical analysis requested by the FDA and look forward to working with the Agency during the review process of our resubmission," said Don M. Bailey, President and CEO of Questcor.
Acthar is currently approved in the U.S. for the treatment of MS exacerbations, nephrotic syndrome and many other conditions. Acthar is not approved in the U.S. for the treatment of IS, a potentially life-threatening disorder that typically begins in the first year of life. However, pursuant to guidelines published by the American Academy of Neurology and the Child Neurology Society, many child neurologists use Acthar to treat infants afflicted with this condition. Questcor is currently pursuing FDA approval for Acthar in the treatment of IS. Previously, the FDA granted Orphan Designation to Acthar for the treatment of IS.
About Questcor
Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar(R) Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "if," "should," "forecasts," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:
- Questcor's ability to continue to successfully implement its Acthar-centric business strategy, including its expansion in the MS marketplace; - Questcor's ability to manage its sales force expansion; - FDA approval of and the market introduction of competitive products and our inability to market Acthar in IS prior to approval of IS as a labeled indication; - Questcor's ability to operate within an industry that is highly regulated at both the Federal and state level; - Regulatory changes or actions including Federal or State health care reform initiatives; - Questcor's ability to accurately forecast the demand for its products; - The gross margin achieved from the sale of its products; - Questcor's ability to estimate the quantity of Acthar used by government entities and Medicaid-eligible patients; - That the actual amount of rebates and chargebacks related to the use of Acthar by government entities and Medicaid-eligible patients may differ materially from Questcor's estimates; - Its expenses and other cash needs for upcoming periods; - The inventories carried by Questcor's distributors, specialty pharmacies and hospitals; - Volatility in Questcor's monthly and quarterly Acthar shipments and end-user demand; - Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all; - Questcor's ability to attract and retain key management personnel; - Questcor's ability to utilize its NOLs to reduce income taxes on taxable income; - Research and development risks, including risks associated with Questcor's sNDA for IS and its preliminary work in the area of nephrotic syndrome; - Uncertainties regarding Questcor's intellectual property; - The uncertainty of receiving required regulatory approvals in a timely way, or at all; - Uncertainties in the credit and capital markets and the impact a further deterioration of these markets could have on Questcor's investment portfolio; - As well as the risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2008 and other documents filed with the Securities and Exchange Commission.
The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For more information, please visit www.questcor.com or www.acthar.com